Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study.

Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study. - ctDNA for MRD with AML after transplant.KSGCT1702(ctDNA)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033003

Enrollment

Registered

2018-06-15

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia, Myelodysplastic Syndromes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Any patient (age >= 20 yo and =< 65 yo) with acute myelogenous leukemia (except for acute promyelocytic leukemia) or myelodysplastic syndromes by WHO2008 criteria 2. Any patient with any disease status or any history/sensitivity of chemotherapy at allogeneic stem cell transplant 3. Patient must have adequate tumor samples at diagnosis or relapse available for analyses (tumor proportion more than 20%) 4. Any patient who have no history of allogeneic stem cell transplant, for whom an myeloablative allogeneic stem cell transplant is warranted 5. Any patient who have signed informed consent available with regard to this study

Exclusion criteria

Exclusion criteria: 1. Any patient who decline to register 2. Any patient who are considered as inappropriate to register by attending physician

Design outcomes

Primary

Measure	Time frame
To evaluate 1-year cumulative incidence of relapse rate according to circulating tumor DNA status post allogeneic hematopoietic stem cell transplant	—

Secondary

Measure	Time frame
1. To evaluate 1-year overall survival rate according to circulating tumor DNA status post allogeneic hematopoietic stem cell transplant 2. To compare the utility of circulating tumor DNA status and conventional biomarkers 3. To compare the profiles of the somatic mutation, gene expression, and immunological cell status between diagnostic and relapsed samples from bone marrow or peripheral blood	—

Countries

Japan

Contacts

Public ContactKazuaki Yokoyama

Research Hospital, The Institute of Medical Science, The University of Tokyo Department of Hematology/Oncology

ksgctdc@ksgct.net03-3443-8111

Outcome results